Nasus Pharma

Nasus Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Nasus Pharma (NSRX) as of Oct 27, 2026 is 84.22 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 43.41 % — a change of 94.03% (higher).

FCF Conversion

84.22 %

YoY

94.03%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Nasus Pharma is 2025 84.22 % . FCF Conversion Rate (FCF/EBITDA) of Nasus Pharma was 2024 43.41 % . It decreases by 94.03% higher compared to the previous year.

The Nasus Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
70.78 USD
Jan 1, 2023
97.91 USD
Jan 1, 2024
43.41 USD
Jan 1, 2025
84.22 USD
The Nasus Pharma FCF Conversion history
YEARFCF ConversionYoY
84.22 %+94.03%
43.41 %-55.66%
97.91 %+38.33%
70.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nasus Pharma Stock analysis

What does Nasus Pharma do? Nasus Pharma Ltd is an Israel-based pharmaceutical company specializing in microsphere technology for intranasal powder-based drug delivery systems. The firm manufactures pharmaceutical preparations designed for rapid, non-invasive administration of medications targeting conditions like anaphylaxis and opioid overdose. Their products focus on fast absorption, ease of use, and effectiveness in emergency scenarios, enabling caregivers, non-professionals, and medical professionals to administer life-saving treatments without specialized training. Nasus Pharma Ltd's formulations aim to improve access to critical medications by simplifying administration in urgent situations. The company's primary products are intranasal powder-based drug delivery systems utilizing microsphere technology. These systems are tailored for conditions requiring immediate intervention, such as anaphylaxis and opioid overdose. The firm targets medical doctors, emergency nurses, and caregivers as key buyers, emphasizing the products' role in critical care settings where speed and simplicity are essential. Nasus Pharma Ltd positions itself as a provider of accessible emergency treatments that bridge gaps in traditional medical administration. Nasus Pharma Ltd's business model centers on developing and commercializing pharmaceutical preparations that leverage microsphere technology for intranasal delivery. The company focuses on creating solutions for life-saving treatments that can be administered by non-specialists, thereby expanding the reach of critical medications. By addressing the need for rapid, non-invasive drug delivery in emergencies, Nasus Pharma Ltd caters to healthcare providers and emergency responders who require reliable, easy-to-use products during critical incidents. Nasus Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nasus Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Nasus Pharma is 84.22 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Nasus Pharma changed from 43.41 % to 84.22 %, representing a 94.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Nasus Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Nasus Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nasus Pharma

All Key Metrics — Nasus Pharma